Key Points
- Director Robert James Wills bought 10,000 Alpha Cognition shares at an average price of $9.62, investing $96,200 and increasing his position by 44.96% to 32,241 shares.
- Alpha Cognition reported quarterly revenue of $6.0 million, above estimates, but its loss of $0.40 per share slightly missed expectations. The company continues to report significant negative margins and analysts expect a full-year loss.
- Analysts remain broadly bullish, with five Buy ratings and a consensus target price of $18, compared with the stock’s recent opening price of $9.75.
Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) Director Robert James Wills acquired 10,000 shares of Alpha Cognition stock in a transaction on Friday, August 21st. The stock was purchased at an average price of $9.62 per share, with a total value of $96,200.00. Following the purchase, the director owned 32,241 shares of the company's stock, valued at $310,158.42. The trade was a 44.96% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Alpha Cognition Stock Performance
ACOG stock opened at $9.75 on Tuesday. The company has a market capitalization of $212.34 million, a P/E ratio of -8.86 and a beta of 2.31. The business has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $6.69. Alpha Cognition Inc. has a twelve month low of $4.50 and a twelve month high of $10.14.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.01). Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. The business had revenue of $6.00 million during the quarter, compared to analyst estimates of $4.38 million. Research analysts predict that Alpha Cognition Inc. will post -1.38 EPS for the current fiscal year.
Analyst Ratings Changes
ACOG has been the topic of a number of recent research reports. HC Wainwright lifted their price objective on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, August 17th. Raymond James Financial began coverage on Alpha Cognition in a report on Friday, July 10th. They set an "outperform" rating and a $20.00 price target on the stock. Wall Street Zen upgraded Alpha Cognition from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Craig Hallum reaffirmed a "buy" rating and set a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. Finally, Maxim Group started coverage on Alpha Cognition in a research report on Friday, May 29th. They set a "buy" rating and a $12.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Alpha Cognition presently has a consensus rating of "Buy" and a consensus target price of $18.00.
Read Our Latest Research Report on ACOG
Institutional Trading of Alpha Cognition
Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC acquired a new position in shares of Alpha Cognition during the second quarter worth about $112,000. Massar Capital Management LP purchased a new stake in Alpha Cognition in the 2nd quarter valued at approximately $116,000. Two Sigma Investments LP purchased a new stake in Alpha Cognition in the 3rd quarter valued at approximately $148,000. Connective Capital Management LLC acquired a new position in Alpha Cognition during the 3rd quarter worth approximately $312,000. Finally, ACT Capital Management LLC purchased a new position in shares of Alpha Cognition during the 4th quarter worth approximately $335,000.
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
